

## **Molecular Templates Collaborates with the MD Anderson Cancer Center on Research of MT-3724 in Chemo-Resistant Aggressive B-Cell Lymphomas**

GEORGETOWN, Tex. – (MARKETWIRED) – October 8<sup>th</sup>, 2015 – Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of next generation immunotoxin therapies called Engineered Toxin Bodies (ETBs) announced today a research collaboration with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”). Under the Material Transfer Agreement, Molecular Templates will provide MD Anderson with MT-3724, the Company’s novel CD20 internalizing immunotoxin currently in human clinical trials, to evaluate in several proprietary chemo-resistant aggressive b-cell lymphoma models.

The research collaboration will focus on evaluating MT-3724 as a single agent and in combination with lenolidomide in various in vitro and in vivo primary tumor model systems of chemo-resistant B-cell lymphomas. The research will also aim to elucidate CD20 expression and localization effects of MT-3724 in these lymphomas.

“We are excited about this research collaboration with MD Anderson and their interest in evaluating MT-3724’s anti-tumor activity in this aggressive and treatment resistant form of lymphomas,” said Eric Poma, Chief Executive Officer at Molecular Templates. “Our ongoing Phase I study in non-Hodgkin’s lymphoma with MT-3724 is showing early signs of activity in aggressive disease. We look forward to further characterizing the activity profile of MT-3724 as a single agent as well as in combination with other promising agents in the treatment of diffuse large B-cell lymphomas.”

### **About Molecular Templates**

Molecular Templates is a biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs). Engineered Toxin Bodies are targeted biologic therapies that incorporate the Company’s next-generation de-immunization technology and immuno-oncology approach – Antigen Seeding Technology (AST). The company is pursuing the development of various leads across a wide range of cancers.

Jason Kim  
President & CFO  
512-869-1555